While Roche has an early lead, Quest recently made key moves to improve its position in the AD patient-initiated blood testing market.
Subscribe today for access to
Articles and Reports
Dx Deal Roundup: A Major Proteomics Merger, Ginkgo Makes Pharma Inroads, and More Legal Woes for Illumina
As is usual at this time of year, deals in the diagnostics industry were up, both in terms of volume and value.
Here are what G2 Intelligence considers the three most significant deals announced in the period from late August to early September.
A strategic partnership with Google enables more accurate whole genome sequencing with machine learning.
Release of second-generation Cologuard test data and recently announced partnerships aim to position company well for the future.
The national retailer recently signed a deal with Simple HealthKit to provide Walmart customers online access to at-home diagnostic test kits.
A recent report offers new insight into bankruptcy trends within the sector starting before the COVID-19 pandemic.
April was among the busiest months, in recent memory, in terms of both deal volume and significance in the diagnostics industry.
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
Genomics software developer Allelica to collaborate with Taiwanese precision medicine firm to develop a multi-ancestry breast cancer test.
There were three notable CDx alliances announced in January 2023, all of which involved cancer-related solutions.
Deals involving the development and commercialization of new cancer diagnostics and treatments were the most common in December.
Having twice failed to disrupt health care, Amazon opts for a different strategy this time around—and it may just work.